For the Three Months Ended March 31, 2024

For the Three Months Ended March 31, 2023

Net loss available to Class A ordinary shareholders

$

(9,492

)

$

(9,665

)

(Increase)/Decrease in ProKidney Corp. accumulated deficit for impact of
   subsidiary equity-based compensation

1,640

2,457

(Increase)/Decrease in ProKidney Corp. additional paid-in capital for exchange
   of Common Units in ProKidney LP for Class A ordinary shares

(2,289

)

–

(Increase)/Decrease in ProKidney Corp. additional paid-in capital for vesting of
   Restricted Common Units in ProKidney LP

(8,672

)

(3,753

)

Change from net loss available to Class A ordinary shareholders and change
   in ownership interest in ProKidney LP

$

(18,813

)

$

(10,961

)